{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958540",
  "id": "02958540",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250616",
  "time": "0846",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krxjf8fgcshq.pdf",
  "summary": "- **Phase I Clinical Trial Update**:  \n  - Safety Review Committee cleared progression to Cohort 5 after no safety signals or dose-limiting toxicities in first four cohorts.  \n  - Trial expanded to six cohorts (from original plan) to evaluate higher doses/longer infusion duration.  \n  - Final readouts expected by **September 2025 quarter**.  \n\n- **Preclinical Efficacy Highlights** (reiterated from prior updates; no new data):  \n  - Neuroprotection: 42% brain tissue rescue in stroke models (Feb 2024), significant TBI neuroprotection (Apr 2025).  \n  - Cardioprotection: 86% efficacy in coronary heart disease model (Oct 2024), reduced arrhythmia incidence (May 2025).  \n\n*No immediate capital markets action required; operational progress aligns with timeline.*",
  "usage": {
    "prompt_tokens": 2072,
    "completion_tokens": 172,
    "total_tokens": 2244,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T23:00:55.279456"
}